Edgar Engleman

Edgar Engleman

Founder chez BOLT BIOTHERAPEUTICS, INC.

Fortune : 2 M $ au 31/03/2024

78 ans
Health Technology
Consumer Services
Finance

Profil

Edgar Engleman, M.D.
is a founding member and Chief Scientific Advisor of Vivo Capital.
Dr. Engleman is a Professor of Pathology and Medicine at the Stanford University School of Medicine, where he established and oversees the Stanford Blood Center, directs his immunology research team, and co-directs the Tumor Immunology and Immunotherapy Research Programs at the Stanford Cancer Institute.
He is an inventor of multiple patented technologies, has authored more than 300 publications in medical and scientific journals, and trained more than 100 graduate and postgraduate students.
Dr. Engleman is the lead inventor of the technology underlying a cancer immunotherapy known as Provenge (Sipulucel-T), which was shown to extend the life of patients who suffer from metastatic prostate cancer.
Provenge is the first in the class of personalized immunotherapeutic agents to be FDA approved for the treatment of cancer.
He is also the lead inventor of the technology underlying the immunotherapies in development at Bolt Biotherapeutics.
Dr. Engleman is the founder or cofounder of a number of biotech companies including Cetus Immune (acquired by Novartis), Genelabs (acquired by GlaxoSmithKline), Dendreon (acquired by Sanpower), and Vivo portfolio companies Medeor, Bolt, and Tranquis.
He currently serves on the boards of Bolt (BOLT) and several private companies including Tranquis, Synapse and Ossium.
He previously served on the boards of REGENEXBIO (RGNX), Eiger (EIGR), Soleno (SLNO), Intermune (ITMN, acquired by Roche), Insmed (INSM), Prestwick (acquired by Biovail) and Semnur (acquired by Sorrento (SRNE).
He received his BA from Harvard College and earned his M.D.
from Columbia University School of Medicine.
In 2017, he received the CABS K Fong Prize in Life Sciences for his biomedical discoveries and contributions.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
12/06/2023 1 278 227 ( 3,35% ) 2 M $ 31/03/2024

Postes actifs de Edgar Engleman

SociétésPosteDébut
BOLT BIOTHERAPEUTICS, INC. Founder 22/01/2015
Founder 01/01/1996
Director/Board Member -
Vivo Co-Invest (S) LP Director/Board Member -
Founder -
Director/Board Member -
Stanford University School of Medicine Corporate Officer/Principal 01/01/1990
Tous les postes actifs de Edgar Engleman

Anciens postes connus de Edgar Engleman

SociétésPosteFin
SOLENO THERAPEUTICS, INC. Director/Board Member 31/12/2017
EIGER BIOPHARMACEUTICALS, INC. Director/Board Member 18/09/2017
░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
░░░░░░ ░░░░░ ░░░░░░░░░░░░░░ ░░░░░░ -
Voir l'expérience en détail de Edgar Engleman

Formation de Edgar Engleman

Harvard University Undergraduate Degree
Columbia University College of Physicians & Surgeons Doctorate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Edgar Engleman

Relations

100 +

Relations au 1er degré

29

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées5
INSMED INCORPORATED

Health Technology

SOLENO THERAPEUTICS, INC.

Health Technology

REGENXBIO INC.

Health Technology

BOLT BIOTHERAPEUTICS, INC.

Health Technology

EIGER BIOPHARMACEUTICALS, INC.

Health Technology

Entreprise privées21

Health Technology

Finance

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Electronic Technology

Health Technology

Health Technology

Health Technology

Health Services

Cetus Immune

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

Vivo Co-Invest (S) LP

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Edgar Engleman